In contrast, MM patients at stage III or with GSTM1 present genotype had lower chances (HR = 0.44, p = 0.009 or HR = 0.46, p = 0.029, respectively) of disease relapse or progression (Table 7). This evidence concerns the gene GSTM1 and Miyoshi myopathy.